GlassScriptPhysician profile
Samantha Mette
NPI 1205477924
$7,041.78
in general payments reported to CMS, 2019-2025
39 companies · $1,569 in 2025
The $1,569 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $37.74 · 2022: $1,441 · 2023: $2,114 · 2024: $1,881 · 2025: $1,569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,563.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,563.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,159.56 | 2021-2025 | |
| Pfizer INC. | $1,026.67 | 2022-2025 | |
| Novo Nordisk INC | $917.90 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $730.12 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $558.20 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $371.18 | 2022-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Glaxosmithkline, LLC. | $271.25 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $240.79 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $149.74 | 2022 | |
| Amgen INC. | $130.91 | 2022-2025 | Prolia, Evenity, Otezla |
| Teva Pharmaceuticals USA, INC. | $129.94 | 2022-2025 | Austedo Xr, Austedo Xr |
| Bayer Healthcare Pharmaceuticals INC. | $125.94 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $114.44 | 2022-2025 | Trintellix |
| Astellas Pharma US INC | $94.55 | 2022-2025 | Veozah, Myrbetriq |
| Axsome Therapeutics, INC. | $86.11 | 2022-2025 | Auvelity |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $84.13 | 2023-2024 | Gardasil 9, Vaxneuvance, Vaxelis |
| E.R. Squibb & Sons, L.L.C. | $79.14 | 2023 | Eliquis, Camzyos |
| Kowa Pharmaceuticals America, INC. | $77.94 | 2022-2023 | Seglentis, Livalo |
| Seqirus USA INC | $70.33 | 2023-2024 | Fluad Quadrivalent, Flucelvax Quadrivalent, Fluad |
| Xeris Pharmaceuticals, INC. | $67.53 | 2023-2024 | Gvoke Hypopen |
| Cranial Technologies, INC | $63.05 | 2023-2025 | Doc Band |
| Currax Pharmaceuticals LLC | $58.39 | 2023 | Contrave, Onzetra Xsail, Nexlizet |
| Dexcom, INC. | $55.16 | 2022-2023 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $44.73 | 2024 | Rexulti |
| Esperion Therapeutics, INC. | $41.66 | 2023-2024 | Nexletol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $37.65 | 2025 | Caplyta |
| Sumitomo Pharma America, INC. | $37.09 | 2024 | Gemtesa |
| Lundbeck LLC | $23.30 | 2024 | Rexulti |
| Verona Pharma, INC. | $22.25 | 2025 | Ohtuvayre |
| Neurocrine Biosciences, INC. | $21.83 | 2024 | Ingrezza |
| Sanofi Pasteur INC. | $20.03 | 2023 | |
| Vanda Pharmaceuticals INC. | $18.55 | 2025 | Fanapt |
| Paratek Pharmaceuticals, INC. | $18.05 | 2022 | |
| Novartis Pharmaceuticals Corporation | $18.04 | 2022 | |
| Corium, LLC | $17.66 | 2025 | Azstarys |
| Aimmune Therapeutics, INC. | $16.57 | 2025 | Zenpep |
| Janssen Pharmaceuticals, INC | $15.44 | 2022 | |
| Phathom Pharmaceuticals, INC. | $13.84 | 2024 | Voquezna |
| Philips North America LLC | $12.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samantha Mette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.